参与COVID-19疫苗试验的社会体验:受试者动机、他人担忧及疫苗推广启示
该研究对31名辉瑞/BioNTech COVID-19疫苗三期试验受试者进行半结构化访谈,主题分析其接种决策与告知他人的体验。不同人口学特征受试者体验相似,主要动机包括结束疫情、保护自己和他人、尽责、示范接种等;常听到对副作用和疫苗研发速度与政治化的担忧,受试者以正常化副作用、去政治化、解释快速流程安全性回应,可纳入疫苗推广信息。
要点
- 受试者参与动机包括结束疫情、保护他人、尽责和示范接种。
- 受试者常听到他人对副作用、研发速度和政治化的担忧。
- 受试者以正常化副作用、去政治化和解释安全性回应担忧。
核心结论
- 受试者报告的参与动机及与担忧者的互动可纳入针对相似人群的COVID-19疫苗推广信息。
研究设计与样本
- 对美国爱荷华城辉瑞/BioNTech COVID-19疫苗三期临床试验点31名受试者进行半结构化访谈。
- 对访谈逐字稿进行主题分析,识别与接种决策相关的共同主题。
主要发现
- 不同年龄、性别、种族/民族和政治倾向的受试者描述的体验大体相似。
- 参与动机包括结束疫情/恢复正常、保护自己和他人、尽责、推广/示范接种、表达助人身份、职业相关动机及支持科学/疫苗。
- 受试者因健康、性别或种族/民族等个人特质感到独特资格通过试验参与提供帮助。
- 受试者报告听到对副作用以及疫苗研发速度和 politicization 的担忧。
- 受试者通过正常化并情境化副作用、去政治化疫苗研发、解释快速研发过程仍然安全来回应。
临床怎么用
- 疫苗推广信息可融入受试者报告的参与动机,针对相似人群设计。
- 推广中可借鉴受试者正常化副作用、去政治化和解释快速研发安全性的沟通策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine hesitancy could undermine the effectiveness of COVID-19 vaccination programs. Knowledge about people's lived experiences regarding COVID-19 vaccination can enhance vaccine promotion and increase uptake. AIM: To use COVID-19 vaccine trial participants' experiences to identify key themes in the lived experience of vaccination early in the vaccine approval and distribution process. METHODS: We interviewed 31 participants in the Iowa City, Iowa US site of the Pfizer/BioNTech COVID-19 vaccine phase 3 clinical trial. While trial participation differs from clinical receipt of an approved vaccine in key ways, it offers the first view of people's lived experiences of potentially receiving a COVID-19 vaccine. The trial context is also useful since decision-making about vaccination and medical research participation often involve similar hopes and concerns, and because the public appears to view even approved COVID-19 vaccines as experimental given their novelty. Semi-structured interviews addressed subjects' experiences, including decision-making and telling others about their trial participation. We analyzed verbatim transcripts of these interviews thematically and identified common themes relevant for vaccination decision-making. RESULTS: Participants across demographic groups, including age, sex/gender, race/ethnicity, and political affiliation, described largely similar experiences. Key motivations for participation included ending the pandemic/restoring normalcy, protecting oneself and others, doing one's duty, promoting/modeling vaccination, and expressing aspects of identity like being a helper, career-related motivations, and support of science/vaccines. Participants often felt uniquely qualified to help via trial participation due to personal attributes like health, sex/gender or race/ethnicity. They reported hearing concerns about side effects and the speed and politicization of vaccine development. Participants responded by normalizing and contextualizing side effects, de-politicizing vaccine development, and explaining how the rapid development process was nevertheless safe. CONCLUSION: These findings regarding participants' reported motivations for trial participation and interactions with concerned others can be incorporated into COVID-19 vaccine promotion messaging aimed at similar populations.
引用
- Wentzell E, Racila AM. The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion. Vaccine. 2021. PMID: 33745730. doi:10.1016/j.vaccine.2021.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。